During separate virtual live events, David R. Gandara, MD, and Alexander Spira, MD, PhD, discussed the timing of durvalumab in non–small cell lung cancer from the PACIFIC trial with participating physicians.
"I think 21 to 40 days is right where I would think we should be. I’m a little skeptical of giving durvalumab right at the completion of chemoradiation for a variety of reasons.”
—DAVID R. GANDARA, MD
Most of us are trying to get into that 4- to 6-week period. A couple of us try a bit earlier. I’ll tell you my experience is that patients need a little bit of a break, but I think we’re all pretty reasonable. I always say what I like to do is 21 to 40 days, but we always have people who are just not feeling well or need to go on that vacation [from therapy].”
—ALEXANDER SPIRA, MD, PHD
Bispecific Antibodies and ADCs Deliver a Futuristic Horizon Across Lung Cancer Settings
October 23rd 2024Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced non-small cell lung cancer.
Read More